COMMUNIQUÉS West-GlobeNewswire

-
Nombre de droits de vote au 31 mai 2024
03/06/2024 -
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
03/06/2024 -
Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés
03/06/2024 -
New data with daridorexant to be presented at SLEEP 2024
03/06/2024 -
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
03/06/2024 -
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
03/06/2024 -
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
03/06/2024 -
BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique
03/06/2024 -
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
03/06/2024 -
Mesoblast Corporate Presentation at Investor Conference
03/06/2024 -
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
03/06/2024 -
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
03/06/2024 -
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
02/06/2024 -
Le congrès de l’EAACI débute à Valence, en Espagne
02/06/2024 -
Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year
02/06/2024 -
Merus : présentation des données provisoires sur le MCLA-145 en monothérapie et en association avec le pembrolizumab lors du congrès annuel 2024 de l’ASCO®
02/06/2024 -
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
02/06/2024 -
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
02/06/2024 -
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
02/06/2024
Pages